|
|
Volumn 51, Issue 3, 2003, Pages 227-230
|
|
Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors
a
|
|
Author keywords
Advanced solid tumors; Anhydrovinblastine; Phase I
|
|
Indexed keywords
ANHYDROVINBLASTINE;
UNCLASSIFIED DRUG;
VINBLASTINE DERIVATIVE;
ADULT;
AGED;
ANEMIA;
ARTHRALGIA;
ARTICLE;
BLOOD TOXICITY;
BONE MARROW;
CANCER CHEMOTHERAPY;
CLINICAL ARTICLE;
CLINICAL TRIAL;
COLORECTAL CANCER;
CONSTIPATION;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DEHYDRATION;
DOSE RESPONSE;
DRUG BLOOD LEVEL;
DRUG CLEARANCE;
DRUG HALF LIFE;
DRUG INFUSION;
FEBRILE NEUTROPENIA;
FEMALE;
HUMAN;
HYPERTENSION;
KIDNEY FUNCTION;
LEUKOPENIA;
LIVER FUNCTION;
LUNG NON SMALL CELL CANCER;
LUNG SARCOMA;
MALE;
MAXIMUM TOLERATED DOSE;
MYALGIA;
NAUSEA;
NEUROTOXICITY;
NEUTROPENIA;
PAIN;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
SOFT TISSUE SARCOMA;
SOLID TUMOR;
THROMBOCYTOPENIA;
VERTIGO;
VOMITING;
|
|
EID: 0344837701
PISSN: 03445704
EISSN: None
Source Type: Journal
DOI: 10.1007/s00280-002-0566-8 Document Type: Article |
|
Times cited : (13)
|
|
References (6)
|
